Stockreport

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

FRESENIUS SE S/ADR  (FSNUY) 
NASDAQ:AMEX Investor Relations: fresenius.com/index
PDF Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous formulation approved by the FDA [Read more]